Zuranolone for the Treatment of Adults With Major Depressive Disorder: A Randomized, Placebo‐Controlled Phase 3 Trial
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Objective This study assessed the efficacy and safety of a 14-day treatment course of once-daily zuranolone 50 mg, an investigational oral positive allosteric modulator of the γ-aminobutyric acid type A (GABA A ) receptor, for the treatment of major depressive disorder. Methods Patients 18-64 years of age with severe major depressive disorder were enrolled in this randomized, double-blind, placebo-controlled trial. Patients self-administered zuranolone 50 mg or placebo once daily for 14 days. The primary endpoint was change from baseline in total score on the 17-item Hamilton Depression Rating Scale (HAM-D) at day 15. Safety and tolerability were assessed by incidence of adverse events. Results Of 543 randomized patients, 534 (266 in the zuranolone group, 268 in the placebo group) constituted the full analysis set. Compared with patients in the placebo group, patients in the zuranolone group demonstrated a statistically significant improvement in depressive symptoms at day 15 (least squares mean change from baseline HAM-D score, -14.1 vs. -12.3). Numerically greater improvements in depressive symptoms for zuranolone versus placebo were observed by day 3 (least squares mean change from baseline HAM-D score, -9.8 vs. -6.8), which were sustained at all visits throughout the treatment and follow-up periods of the study (through day 42, with the difference remaining nominally significant through day 12). Two patients in each group experienced a serious adverse event; nine patients…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A recently published phase III trial had very positive results, showing significant clinical improvements at day 3 and sustained through the whole duration of the study at day 42 [189].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [189]
Citations
Cites
James, S. L., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdela, J., Abdelalim, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32279-7 · Cited by 13,867
Self-citationRush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Wang, P. S., Lane, M., Olfson, M., Pincus, H. A., Wells, K. B., & Kessler, R. C. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.629 · Cited by 2,695
Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050045 · Cited by 2,442
Prevalence of depression symptoms in US adults before and during the COVID-19 pandemic
Ettman, C. K., Abdalla, S. M., Cohen, G. H., Sampson, L., Vivier, P. M., & Galea, S. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.19686 · Cited by 2,138
Mokdad (2018) · doi:10.1001/jama.2018.0158 · Cited by 1,517
Duman, R. S., Sanacora, G., & Krystal, J. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.03.013 · Cited by 1,026
The GABAergic deficit hypothesis of major depressive disorder
Luscher, B., Shen, Q., & Sahir, N. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.120 · Cited by 934
Yan, C.-G., Chen, X., Li, L., Castellanos, F. X., Bai, T.-J., Bo, Q.-J., Cao, J., Chen, G.-M., Chen, N.-X., Chen, W., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1900390116 · Cited by 895
The Descriptive Epidemiology of Commonly Occurring Mental Disorders in the United States
Kessler, R. C., & Wang, P. S. (2008) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.29.020907.090847 · Cited by 888
Meltzer-Brody, S., Colquhoun, H., Riesenberg, R., Epperson, C. N., Deligiannidis, K. M., Rubinow, D. R., Li, H., Sankoh, A. J., Clemson, C., Schacterle, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31551-4 · Cited by 795
Self-citationSSRI Antidepressant Medications: Adverse Effects and Tolerability
Ferguson, J. M. (2001) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v03n0105 · Cited by 669
Hirschfeld, R. M. A. (2001) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v03n0609 · Cited by 661
Numbers and proportions of GABA-immunoreactive neurons in different areas of monkey cerebral cortex
Hendry, S., Schwark, H., Jones, E., & Yan, J. (1987) · The Journal of Neuroscience · doi:10.1523/jneurosci.07-05-01503.1987 · Cited by 601
Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial.
Kanes, S., Colquhoun, H., Gunduz-Bruce, H., Raines, S., Arnold, R., Schacterle, A., Doherty, J., Epperson, C. N., Deligiannidis, K. M., Riesenberg, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31264-3 · Cited by 479
Self-citationRecommendations for the Primary Analysis of Continuous Endpoints in Longitudinal Clinical Trials
Mallinckrodt, C. H., Lane, P. W., Schnell, D., Peng, Y., & Mancuso, J. P. (2008) · Drug Information Journal · doi:10.1177/009286150804200402 · Cited by 354
Effect of Zuranolone vs Placebo in Postpartum Depression
Deligiannidis, K. M., Meltzer-Brody, S., Gunduz-Bruce, H., Doherty, J., Jonas, J., Li, S., Sankoh, A. J., Silber, C., Campbell, A. D., Werneburg, B., et al. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.1559 · Cited by 277
Self-citationGABA levels in CSF of patients with psychiatric disorders
(1980) · American Journal of Psychiatry · doi:10.1176/ajp.137.3.362 · Cited by 270
Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Cosci, F., & Chouinard, G. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506868 · Cited by 265
Trial of SAGE-217 in Patients with Major Depressive Disorder
Gunduz-Bruce, H., Silber, C., Kaul, I., Rothschild, A. J., Riesenberg, R., Sankoh, A. J., Li, H., Lasser, R., Zorumski, C. F., Rubinow, D. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1815981 · Cited by 232
Self-citationLee, V., & Maguire, J. (2014) · Frontiers in Neural Circuits · doi:10.3389/fncir.2014.00003 · Cited by 228
Antidepressant-associated sexual dysfunction: impact, effects, and treatment
Higgins, A. (2010) · Drug, Healthcare and Patient Safety · doi:10.2147/dhps.s7634 · Cited by 227
Benzodiazepine use, misuse, and abuse: A review
Schmitz, A. (2016) · Mental Health Clinician · doi:10.9740/mhc.2016.05.120 · Cited by 186
Posternak, M. A., & Zimmerman, M. (2007) · British Journal of Psychiatry · doi:10.1192/bjp.bp.106.028555 · Cited by 154
Althaus, A. L., Ackley, M. A., Belfort, G. M., Gee, S. M., Dai, J., Nguyen, D. P., Kazdoba, T. M., Modgil, A., Davies, P. A., Moss, S. J., et al. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108333 · Cited by 135
Self-citationMartinez Botella, G., Salituro, F. G., Harrison, B. L., Beresis, R. T., Bai, Z., Blanco, M.-J., Belfort, G. M., Dai, J., Loya, C. M., Ackley, M. A., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00846 · Cited by 129
Self-citationAntonoudiou, P., Colmers, P. L. W., Walton, N. L., Weiss, G. L., Smith, A. C., Nguyen, D. P., Lewis, M., Quirk, M. C., Barros, L., Melón, L. C., et al. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3614121 · Cited by 122
Neurosteroids promote phosphorylation and membrane insertion of extrasynaptic GABA A receptors
Abramian, A. M., Comenencia-Ortiz, E., Modgil, A., Vien, T. N., Nakamura, Y., Moore, Y. E., Maguire, J. L., Terunuma, M., Davies, P. A., & Moss, S. J. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1403285111 · Cited by 115
Khan, A., Fahl Mar, K., Faucett, J., Khan Schilling, S., & Brown, W. A. (2017) · World Psychiatry · doi:10.1002/wps.20421 · Cited by 109
Bushnell, G. A., Stürmer, T., Gaynes, B. N., Pate, V., & Miller, M. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.1273 · Cited by 109
Santhakumar, V., Hanchar, H. J., Wallner, M., Olsen, R. W., & Otis, T. S. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4799-05.2006 · Cited by 101
Amino acid levels in depression: A preliminary investigation
Honig, A., Bartlett, J. R., Bouras, N., & Bridges, P. K. (1988) · Journal of Psychiatric Research · doi:10.1016/0022-3956(88)90001-5 · Cited by 94
Jacob, T. C., Michels, G., Silayeva, L., Haydon, J., Succol, F., & Moss, S. J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1204994109 · Cited by 91
Modgil, A., Parakala, M. L., Ackley, M. A., Doherty, J. J., Moss, S. J., & Davies, P. A. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.10.010 · Cited by 75
Self-citationMann, J. J., Oquendo, M. A., Watson, K. T., Boldrini, M., Malone, K. M., Ellis, S. P., Sullivan, G., Cooper, T. B., Xie, S., & Currier, D. (2014) · Depression and Anxiety · doi:10.1002/da.22278 · Cited by 63
Sayyah, M., Eslami, K., AlaiShehni, S., & Kouti, L. (2016) · Psychiatry Journal · doi:10.1155/2016/5480391 · Cited by 52
Wilbraham, D., Berg, P. H., Tsai, M. C., Liffick, E., Loo, L. S., Doty, E. G., & Sellers, E. M. (2019) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1543 · Cited by 29
Research works printed but not linked: 4
- Keks N, 2016, Aust Prescr, 39, 76
- 10.1016/j.biopsych.2021.07.017 · doi:10.1016/j.biopsych.2021.07.017
- Rapaport MH, 2006, Psychiatry (Edgmont), 3, 50
- Ogawa Y, 2019, Cochrane Database Syst Rev, 6, CD001026
Cited by
Zuranolone for the Treatment of Postpartum Depression
Deligiannidis, K. M., Meltzer-Brody, S., Maximos, B., Peeper, E. Q., Freeman, M., Lasser, R., Bullock, A., Kotecha, M., Li, S., Forrestal, F., et al. (2023) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20220785 · Cited by 192
Self-citationCutler, A. J., Mattingly, G. W., & Maletic, V. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02514-2 · Cited by 192
Thompson, S. M. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01728-8 · Cited by 103
Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression
Vecera, C. M., C. Courtes, A., Jones, G., Soares, J. C., & Machado-Vieira, R. (2023) · Pharmaceuticals · doi:10.3390/ph16111572 · Cited by 48
“A recently published phase III trial had very positive results, showing significant clinical improvements at day 3 and sustained through the whole duration of the study at day 42 [189].”
BackgroundCorreia, A. S., & Vale, N. (2024) · International Journal of Translational Medicine · doi:10.3390/ijtm4010010 · Cited by 57
Metadata
- Authors
- Clayton, A. H., Lasser, R., Parikh, S. V., Iosifescu, D. V., Jung, J., Kotecha, M., Forrestal, F., Jonas, J., Kanes, S. J., & Doherty, J.
- Affiliations
- Nathan Kline Institute for Psychiatric Research (US)
- Venue
- American Journal of Psychiatry
- Published
- 2023-09-01
- Volume
- 180
- Issue
- 9
- Pages
- 676-684
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W4367834204
- Cited by
- 87
- References
- 38
- Citations by year
- 2026: 16 · 2025: 28 · 2024: 24 · 2023: 19
- FWCI
- 13.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- zuranolone, major depressive disorder, 5α-reductase inhibition, antidepressant efficacy, adverse events, tolerability
- MeSH terms
- Adult, Depressive Disorder, Major, Major Depressive Disorder, Humans, Pregnanes, Pregnanolone, Pyrazoles, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.